SAFDAR, Z., JANSA, P., MEHTA, S., PULIDO-ZAMUDIO, T., K SASTRY, B., SITBON, O., … DELCROIX, M. (2021). MACITENTAN TREATMENT EFFECT IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION TAKING SPIRONOLACTONE: POST-HOC ANALYSIS OF THE PHASE 3 SERAPHIN TRIAL. Chest, 160(4), A2284–A2286. https://doi.org/10.1016/j.chest.2021.07.1998

SAFDAR, Z. E. E. N. A. T., P. A. V. E. L. JANSA, S. A. N. J. A. Y. MEHTA, T. O. M. A. S. PULIDO-ZAMUDIO, B. K SASTRY, O. L. I. V. I. E. R. SITBON, R. O. G. E. R. I. O. SOUZA, et al. “MACITENTAN TREATMENT EFFECT IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION TAKING SPIRONOLACTONE: POST-HOC ANALYSIS OF THE PHASE 3 SERAPHIN TRIAL.” Chest 160, no. 4 (October 2021): A2284–86. https://doi.org/10.1016/j.chest.2021.07.1998.

SAFDAR Z, JANSA P, MEHTA S, PULIDO-ZAMUDIO T, K SASTRY B, SITBON O, et al. MACITENTAN TREATMENT EFFECT IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION TAKING SPIRONOLACTONE: POST-HOC ANALYSIS OF THE PHASE 3 SERAPHIN TRIAL. Chest. 2021 Oct;160(4):A2284–6.

SAFDAR, Z. E. E. N. A. T., et al. “MACITENTAN TREATMENT EFFECT IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION TAKING SPIRONOLACTONE: POST-HOC ANALYSIS OF THE PHASE 3 SERAPHIN TRIAL.” Chest, vol. 160, no. 4, Elsevier BV, Oct. 2021, pp. A2284–86. Crossref, doi:10.1016/j.chest.2021.07.1998.

SAFDAR Z, JANSA P, MEHTA S, PULIDO-ZAMUDIO T, K SASTRY B, SITBON O, SOUZA R, TORBICKI A, MARTINEZ E, ZHAO C, DELCROIX M. MACITENTAN TREATMENT EFFECT IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION TAKING SPIRONOLACTONE: POST-HOC ANALYSIS OF THE PHASE 3 SERAPHIN TRIAL. Chest. Elsevier BV; 2021 Oct;160(4):A2284–A2286.